$EQ

Tom Penny sold $192K of EQ

Tom Penny (Principal Accounting Officer) sold 65,000 shares of Equillium, Inc. (EQ) at $2.95 ($0.19M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tom Penny
Published May 29, 2026, 10:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EQ
Neutral
medium confidence
Mentioned
$EQ
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EQNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but 10b5-1 pre-arrangement typically lowers interpretive value versus unscheduled selling.

02

Market read

Traders may monitor EQ for follow-on insider activity, but this specific filing alone is unlikely to drive a major repricing.

03

What to watch

The filing does not reveal remaining insider intent or whether other insiders/funds changed positions around the same time.

Relevance 6/10Novelty 6/10Timing: After-hours/filing timestamp (filed 2026-05-29) for a sale executed 2026-05-28

Background

The article is an SEC Form 4 insider transaction disclosure for Equillium, Inc. (EQ).

Company-level read

Ticker impact

$EQNeutralMedium confidence
Context

Equillium officer Tom Penny sold 65,000 shares in an open-market transaction disclosed on SEC Form 4.

Expected impact

Likely limited immediate price impact; any reaction should be modest and short-lived unless accompanied by other catalysts.

Evidence & confidence

Form 4 shows an officer sale under a pre-arranged 10b5-1 plan and the article provides no accompanying fundamental change (earnings, trial, deal, or guidance).

Market effects

Minimal; this is company-specific insider transaction with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine diversification rather than a bearish view.

Key entities

  • Equillium, Inc.

    Company whose officer sale is disclosed via SEC Form 4.

  • Tom Penny

    Principal Accounting Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EQHighAI 8/10

Equillium stock price target maintained at $20 by Piper Sandler

Piper Sandler maintained a $20 price target for Equillium (EQ), citing Australian regulatory clearance for its EQ504 drug. The stock is down 10% this week. Clear Street also initiated coverage with a $9 target. Equillium plans Phase 1 trials for EQ504, an AhR modulator, with data expected in 2027. The company has a market cap of $91.94M and trades near InvestingPro’s Fair Value estimate.

$EQLow

Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods…

Equillium, Inc. (EQ) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On October 5, 2026, Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme for its Pha